LUSPATERCEPT
Background and Date of Approval
Luspatercept contains luspatercept as its active component. It is a medication developed to treat certain types of anemia, particularly anemia associated with two rare blood disorders: beta-thalassemia and myelodysplastic syndromes (MDS). The pharmacological class of luspatercept is “erythroid maturation agent.” The U.S. FDA initially approved luspatercept on November 8, 2019.
Uses
It treats anemia associated with two rare blood disorders: beta-thalassemia and myelodysplastic syndromes (MDS). Beta-thalassemia is an inherited blood disorder that affects the production of hemoglobin, the protein responsible for carrying oxygen in red blood cells. Myelodysplastic syndromes (MDS) are a group of bone marrow disorders characterized by ineffective blood cell production.
How is it administered?
To use Luspatercept, follow the instructions provided by your healthcare provider or as indicated on the medication label. It is typically administered as an injection. The exact dosing and administration instructions may vary based on the specific condition being treated.
Side Effects
Common side effects of luspatercept may include headache, fatigue, dizziness, nausea, joint pain, bone pain, muscle pain, and injection site reactions such as pain, redness, or swelling. Although less common, serious side effects can include blood clots, hypertension, stroke, heart attack, hemorrhage, and allergic reactions.
Warnings
Luspatercept carries important warnings that should be considered before starting treatment. These warnings include an increased risk of thrombotic events such as blood clots, venous thromboembolism, stroke, and heart attack. Hypertension (high blood pressure) and hemorrhage (excessive bleeding) are potential risks associated with luspatercept use. Additionally, this medication may develop or worsen bone marrow fibrosis, a condition characterized by excessive scar tissue formation in the bone marrow. There is a potential risk of hypersensitivity reactions, although rare. Hepatotoxicity (liver damage), renal toxicity (kidney damage), interference with iron metabolism, increased risk of infections, and exacerbation of pre-existing retinopathy are other warnings associated with this medication.
Precautions
Carefully consider the warnings associated with the medication, such as the increased risk of thrombotic events and potential harm to a developing fetus; take the recommended precautions. It is important to regularly monitor blood pressure, liver function, kidney function, and iron levels test during the treatment. Be cautious if you have a history of blood clots, clotting disorders, or significant bleeding episodes. Limit or avoid alcohol consumption; follow the dosing and administration instructions provided by your healthcare provider. By taking these precautions, you can help ensure the safe and effective use of luspatercept for your specific condition.
Word of Advice
Regular monitoring of blood pressure, liver function, kidney function, and iron levels is typically recommended during treatment with luspatercept. Any abnormalities or changes in these parameters should be promptly addressed and managed accordingly.
Patients with a history of blood clots, clotting disorders, or significant bleeding episodes require close monitoring during treatment due to the increased risk of thrombotic events and haemorrhage. Promptly report any signs of bleeding, including unusual bruising, nosebleeds, or blood in the urine or stool, to your healthcare provider.
Discuss the potential risks of luspatercept during pregnancy or breastfeeding with your healthcare provider. Communicate openly with your healthcare provider about your complete medical history, ongoing treatments, and any concerns you may have. Maintaining regular communication with your healthcare provider will help maximise the benefits of this medicine while minimising potential risks.
References
Lonza Biologics Tuas Pte Ltd, European Medicines Agency, [Revised on 25 June 2020] [Accessed on 17th June 2023], https://www.ema.europa.eu/en/documents/product-information/reblozyl-epar-product-information_en.pdf Acceleron Pharma, Inc, US Food and Drug Administration, [Revised on April 2020] [Accessed on 17th June 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761136orig2lbl.pdf
Frequently Asked Questions
Can luspatercept be used in children?
Luspatercept is not approved for use in children, as its safety and efficacy have not been established in pediatric populations. It is primarily indicated for adult patients with specific medical conditions.
Can luspatercept be used in patients with kidney disease?
Luspatercept may require dose adjustment or close monitoring in patients with kidney disease. Your healthcare provider will assess your kidney function and determine the appropriate dose or any necessary precautions based on your circumstances.
Can luspatercept be used during chemotherapy or radiation therapy?
The use of luspatercept in conjunction with chemotherapy or radiation therapy has yet to be extensively studied. Discussing your treatment plan with your healthcare provider to determine the most appropriate approach and any potential interactions or effects is important.
Can luspatercept be used in patients with a history of cardiovascular disease?
Luspatercept should be used cautiously in patients with a history of cardiovascular disease, as it may increase the risk of cardiovascular events such as heart attack or stroke. Your healthcare provider will assess your cardiovascular health and determine the suitability of this medication treatment.
Can luspatercept cause any side effects in patients with a history of bleeding disorders?
Patients with a history of bleeding disorders should be closely monitored during luspatercept treatment due to the increased risk of hemorrhage. Discussing your medical history with your healthcare provider to determine the appropriate precautions and monitoring plan is important.
Can luspatercept cause fertility problems?
Luspatercept may affect fertility in both males and females. If you have concerns about fertility or family planning, discussing this with your healthcare provider before starting treatment with luspatercept is important. They can provide guidance and recommendations based on your circumstances.